USIL Therapeutics
USIL Therapeutics is a Luxembourg-based biotechnology company founded in 2025 developing first-in-class radioprotective medical countermeasures (UT-241 auto-injector and UT-242 IV infusion) for Acute Radiation Syndrome, serving defence ministries, first responders, civil protection agencies, and healthcare systems in Europe and allied regions.
- Company typePrivate
- Founded2025
- HeadquartersLuxembourg, Luxembourg
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
USIL Therapeutics firmographics
Firmographics- Name
- USIL Therapeutics
- Legal name
- USIL Therapeutics S.A.
- Website
- https://usil-therapeutics.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- USIL Therapeutics is a Luxembourg-based biotechnology company founded in 2025 developing first-in-class radioprotective medical countermeasures (UT-241 auto-injector and UT-242 IV infusion) for Acute Radiation Syndrome, serving defence ministries, first responders, civil protection agencies, and healthcare systems in Europe and allied regions.
- Ownership category
- akta.pro rank
USIL Therapeutics industry classification
Industry- Product category
- Radioprotective Medical Countermeasures
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Radiation Safety, Dosimetry & Regulatory Compliance (Nuclear Medicine) (HLAIAGAJ)
Keywords
Where USIL Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Luxembourg
- HQ country
- Luxembourg
- HQ region
- Europe
Offices1 record
Markets served
USIL Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Medical Countermeasure Sales to Government/Institutional Buyers: Revenue from selling radioprotective medical countermeasures (UT-241 and UT-242) to defence ministries, first responders, civil protection agencies, hospitals, and emergency response systems. As a pre-revenue company (founded 2025), commercial revenue is anticipated post-2029 market entry.
- Licensing Royalties: Portfolio of multiple patents covering a radioprotective molecule with protection across EU, US, and Japan may generate licensing revenue from third-party commercialization rights.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels3 records
USIL Therapeutics product offering
Product offeringCore offering
USIL Therapeutics develops first-in-class whole-body radioprotective medical countermeasures for Acute Radiation Syndrome (ARS). Its pipeline includes UT-241, a ready-to-use intramuscular auto-injector designed for rapid field deployment by first responders and military personnel, and UT-242, an intravenous formulation for prolonged hospital-based therapeutic coverage. The dual-use platform addresses both acute high-dose radiation exposure and prolonged lower-dose radiation scenarios relevant to defence, civilian preparedness, and space missions.
Differentiator
Problem solved
Functional benefit
Brands
- UT-241: IM Auto-Injector - a ready-to-use integral drug-device combination for rapid intramuscular administration, designed for time-critical scenarios involving first responders and exposed populations.
- UT-242
Products and services
- UT-241 IM Auto-Injector
Quantifiable outcome
- Phase one pre-clinical trials completed with FDA review confirming safety for human administration
- +2 more outcomes
Companies that use USIL Therapeutics
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
USIL Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
USIL Therapeutics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- European Space Agency (ESA)coreUSIL Therapeutics selected by ESA for in-orbit validation mission aboard the International Space Station. The study evaluates USIL's whole-body radioprotection approach under microgravity and elevated cosmic radiation to assess stability, biological response, and performance in space-relevant conditions. ESA-funded project supports dual-use development across spaceflight, defence, and civilian preparedness.
- YURI (Yuri Gravity)corePartnership with YURI for ISS validation mission. YURI is a Luxembourg company specializing in payloads to Low Earth Orbit. Stefan Dimitrov-Lübcke, YURI LUX Managing Director, serves as Space Advisor to USIL Therapeutics.
- French Alternative Energies and Atomic Energy Commission (CEA)coreTESAR project consortium partner coordinated by USIL. CEA brings expertise in alternative energies and atomic energy research. The TESAR project delivers the first universal medical countermeasure for acute radiation syndrome fully developed and manufactured within Europe.
- European CommissioncoreUSIL holds two formal mandates within the European Commission's Joint Industrial Cooperation Forum (ICF) under HERA. TESAR project awarded multi-million EUR grant and STEP Seal under EU4Health Programme scoring 93/100. Selected participant in European Defence Fund Resilience 2026 work programme and EUDIS Business Accelerator Cohort 2.
- SpaceXminorCollaboration mentioned for ISS testing of the compound on International Space Station for potential space applications protecting astronauts and pilots.
- NATO Support and Procurement Agency (NSPA)coreAlignment with NATO procurement frameworks through NSPA for access to NATO-aligned stakeholders across Europe. Company positioned for institutional integration within defence coordination frameworks.
- European Health Emergency Preparedness and Response Authority (HERA)coreICF operates under HERA authority. USIL contributes to working groups addressing supply-chain resilience, manufacturing readiness, innovation, access, and strategic preparedness for medical countermeasures, supporting EU Medical Countermeasures Strategy implementation.
Scale indicators7 records
USIL Therapeutics competitors and assessment
Company assessmentEmerging players
- Soligenix: Soligenix is a late-stage biopharmaceutical company developing medical countermeasures for radiation injury (e.g., SGX301 for cutaneous radiation injury) and other biodefense indications. Comparable as a countermeasure-focused specialty biotech pursuing government procurement pathways, though smaller and less capitalized than USIL's institutional backers.
- Tonix Pharmaceuticals: Tonix is developing countermeasures for radiation and biodefense indications alongside its CNS pipeline, pursuing government contracts similar to USIL's strategy. Smaller and earlier stage than USIL but operates in an overlapping medical countermeasure regulatory and procurement space.
Broad incumbents
- Bavarian Nordic: Bavarian Nordic is an established vaccine and biodefense company with government stockpiling contracts (e.g., smallpox, Ebola) and European institutional backing. Comparable as a European-headquartered biodefense countermeasure supplier leveraging both EU and US procurement channels.
- Landauer: Landauer is a long-standing provider of radiation dosimetry and monitoring solutions used across medical, nuclear energy, and defence settings. Comparable as a radiation-safety incumbent serving the institutional customers USIL also targets, though via monitoring services rather than pharmaceutical countermeasures.
- Emergent BioSolutions: Emergent is a publicly traded, established biodefense company with a broad portfolio of medical countermeasures (anthrax vaccines, smallpox therapies, etc.) and deep government procurement relationships. It represents the incumbent model USIL aspires to scale into across the radiological countermeasure niche.
- Mirion Technologies: Mirion is a global incumbent in radiation safety, detection, dosimetry, and shielding products serving nuclear energy, defence, and medical markets. While Mirion sells equipment and services rather than drugs, it serves the same customer base (defence ministries, civil protection agencies, nuclear operators) and frames the broader radiation preparedness market USIL addresses.
- SIGA Technologies: SIGA develops and supplies TPOXX, an antiviral stockpiled by governments for smallpox preparedness, and operates a government-focused commercial model. While focused on a different threat, SIGA exemplifies the public-health stockpiling business model USIL targets for ARS countermeasures.
Direct peers
- Humanetics Corporation: Humanetics is the most direct comparable, developing BIO 300, a small-molecule radioprotectant intended to address acute radiation syndrome and radiation injury for military and civilian applications. Both companies target the same ARS unmet need with similar regulatory pathways (FDA, BARDA, DoD stockpiling).
Market position
Customer concentration
USIL Therapeutics social profiles
Digital presenceUSIL Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
USIL Therapeutics leadership team
Management profileNumber of profiles
Profiles11 records
USIL Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
USIL Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about USIL Therapeutics
What does USIL Therapeutics do?
USIL Therapeutics develops first-in-class whole-body radioprotective medical countermeasures for Acute Radiation Syndrome (ARS). Its pipeline includes UT-241, a ready-to-use intramuscular auto-injector designed for rapid field deployment by first responders and military personnel, and UT-242, an intravenous formulation for prolonged hospital-based therapeutic coverage. The dual-use platform addresses both acute high-dose radiation exposure and prolonged lower-dose radiation scenarios relevant to defence, civilian preparedness, and space missions.
Is USIL Therapeutics a public or private company?
USIL Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was USIL Therapeutics founded?
USIL Therapeutics was founded in 2025. It employs 1 to 10 people.
Where is USIL Therapeutics based?
USIL Therapeutics is headquartered in Luxembourg, Luxembourg, in the Europe region.
How does USIL Therapeutics make money?
Two revenue lines are on record. Medical Countermeasure Sales to Government/Institutional Buyers are the primary driver. The others are licensing Royalties.
Who are USIL Therapeutics's main competitors?
Emerging players on record are Soligenix and Tonix Pharmaceuticals. Broad incumbents are Bavarian Nordic, Landauer, Emergent BioSolutions, Mirion Technologies and SIGA Technologies. Humanetics Corporation is listed as a direct peer.
Does USIL Therapeutics have an API?
No public API is recorded for USIL Therapeutics.
What industry is USIL Therapeutics in?
USIL Therapeutics's product category is Radioprotective Medical Countermeasures. Its primary akta.pro industry code is HLAIAGAJ, Radiation Safety, Dosimetry & Regulatory Compliance (Nuclear Medicine). Its NAICS code is 5417 and its SIC code is 3841.